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Available online 6 December 2014Abstract Mesenchymal stromal cells (MSCs) support the growth and differentiation of normal hematopoietic stem cells
(HSCs). Here we studied the ability of MSCs to support the growth and survival of leukemic stem cells (LSCs) in vitro. Primary
leukemic blasts isolated from the peripheral blood of 8 patients with acute myeloid leukemia (AML) were co-cultured with
equal numbers of irradiated MSCs derived from unrelated donor bone marrow, with or without cytokines for up to 6 weeks.
Four samples showed CD34+CD38− predominance, and four were predominantly CD34+CD38+. CD34+ CD38− predominant
leukemia cells maintained the CD34+ CD38− phenotype and were viable for 6 weeks when co-cultured with MSCs compared to
co-cultures with cytokines or medium only, which showed rapid differentiation and loss of the LSC phenotype. In contrast,
CD34+ CD38+ predominant leukemic cells maintained the CD34+CD38+ phenotype when co-cultured with MSCs alone, but no
culture conditions supported survival beyond 4 weeks. Cell cycle analysis showed that MSCs maintained a higher proportion of
CD34+ blasts in G0 than leukemic cells cultured with cytokines. AML blasts maintained in culture with MSCs for up to 6 weeks
engrafted NSG mice with the same efficiency as their non-cultured counterparts, and the original karyotype persisted after
co-culture. Chemosensitivity and transwell assays suggest that MSCs provide pro-survival benefits to leukemic blasts through
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(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction Helsinki for the use of samples for research according to theAcute myeloid leukemia (AML) is the best studied human
tumor for cancer stem cell research and has contributed to
our understanding of the cancer stem cell model (Dick, 2008;
Lapidot et al., 1994; Bhatia et al., 1998). Since leukemic
stem cells (LSCs) are considered to be associated with
relapse, chemotherapy resistance and overall poor prognosis
(Eppert et al., 2011; Gentles et al., 2010), targeting LSCs has
been proposed as a promising strategy for cure of AML (Saito
et al., 2010, 2013; Misaghian et al., 2009). Immuno-deficient
mouse xenotransplantation models are the gold standard
assay for LSCs, and SCID leukemia-initiating cells (SL-ICs) are
thought to possess the functional and molecular character-
istics of LSCs (Lapidot et al., 1994; Bhatia et al., 1998).
However SL-ICs in primary human AML are rare and
heterogeneous (Eppert et al., 2011; Gentles et al., 2010;
Sarry et al., 2011), therefore patient-derived human primary
AML samples are not always sufficient to allow hematopoi-
etic reconstitution in xenotransplantation model. Develop-
ment of an in vitro LSC culture system would facilitate
further advances in cancer stem cell research and assist in
the development of novel therapeutic targets of LSCs
(Kennedy and Barabe, 2008). Mesenchymal stromal cells
(MSCs) are known to support the growth and differentiation
of normal hematopoietic stem cells (HSCs) (de Lima et al.,
2012; Keating, 2012; Robinson et al., 2006) through various
molecular signals such as CXCL12-mediated CXCR4 signaling
and Wnt-induced β-catenin signaling. Murine stromal cell
lines and growth factors have been used to expand primary
human AML blasts in vitro, however the leukemic blasts
eventually lost their original CD34+CD38− phenotype in
long-term in vitro culture systems (Klco et al., 2013; van
Gosliga et al., 2007). We hypothesized that human MSCs may
also provide a survival benefit for LSCs since they share
similar molecular signatures with normal HSCs (Eppert et al.,
2011; Gentles et al., 2010), and MSC co-culture systems can
be utilized for long-term maintenance of LSCs in vitro even
without growth factors. Furthermore, understanding rela-
tionships between AML and its stromal niche is of importance
for defining mechanisms of leukemic persistence and
preventing leukemic relapse. Here we co-cultured human
primary leukemic blasts with unrelated bone marrow (BM)
derived human MSCs and characterized the phenotype and
function of leukemic blasts and their ability to engraft in a
xenotransplantation mouse model.Materials and methods
Primary leukemic samples
Peripheral blood samples were collected from eight patients
with AML (mean age 53, range 23–74: Table 1). Written
informed consent was obtained from the patients and
healthy volunteers in accordance with the Declaration ofrequirements of the Institutional Review Board of the
National Heart, Lung, and Blood Institute and MD Anderson
Cancer Center. Cells were thawed in human cell culture
medium [RPMI 1640 (Life Technologies, Carlsbad, CA) supple-
mented with 10% human AB serum (Gemini Bio-Products, West
Sacrament, CA), 2 mM L-glutamine, 100 U/ml penicillin and
100 μg/ml streptomycin (Life Technologies, Carlsbad, CA)].MSC isolation, culture and expansion
After obtaining informed consents, BM aspirates were
collected from healthy volunteers in the Department of
Transfusion Medicine, National Institutes of Health. The BM
aspirates were plated in 75 cm2 flask in MSC medium
consisting of MEMα (Life Technologies, Carlsbad, CA)
supplemented with 20% fetal bovine serum (Sigma-Aldrich,
St. Louis, MO), and 1% L-glutamine (Life Technologies,
Carlsbad, CA). Non-adherent cells were removed after
24 h, and the adherent cells were cultured for approximate-
ly 14 days with twice weekly MSC medium changes. The cells
were harvested using 0.05% trypsin-EDTA (Life Technologies,
Carlsbad, CA) when 70% confluence was achieved and used
for further expansion. The cells were plated at a density of
4 × 103/cm2 in four-layer cell factory flasks (Thermo
Scientific Nunc™ Cell Factory™ Systems, Waltham, MA) in
MSC medium. Serial passages were obtained once the cells
reached 70% confluence and subsequently expanded MSCs
were harvested and cryopreserved in liquid nitrogen.
Passage 4 MSCs were thawed in human cell culture medium
and were irradiated with 50 Gy. The cells were then
plated at selected density in flat bottom plates one day
before co-culture experiments to allow reticular network
formation.Isolation of primary leukemic cells and co-culture
with MSCs
Cells from primary leukemic samples were stained with
antibodies to CD34-APC (clone 581, BD Biosciences, San Jose,
CA), and lineage antibodies, including CD2 (clone TS1/8,
Biolegend, San Diego, CA), CD3 (clone S4.1PB), CD14 (clone
clone TüK4), and CD19 (clone SJ25-C1)-Pacific Blue
(Invitrogen, Carlsbad, CA), as well as Propidium Iodide (PI:
Molecular Probes, Eugene, OR). Lineage negative (Lin−) CD34+
cells were sorted on FACSAria II cell sorter (BD, Franklin Lakes,
NJ) and 2.5 × 105 cells were co-cultured with an equal number
of irradiated MSCs in 24-well flat bottom plates with or
without cytokines (150 ng/ml FLT3-ligand, 150 ng/ml Stem
cell factor (SCF), 50 ng/ml Interleukin-3 (IL-3)). In control
wells, Lin−CD34+ cells were cultured without MSC support
in the presence or absence of the same cytokines. In all wells,
culture media were replaced twice weekly. In transwell
assays, sorted Lin−CD34+ cells were placed in the transwell
insert (Costar Transwell® Permable Supports: 0.4 μm
Table 1 Characteristics of AML patients.
UPN Age Sex AML subtype Karyotype Status at sample collection Leukemia phenotype
UPN1 71 F AML/MDS 5q−, 7q−, 8+ Relapse CD34+CD38− predominant
UPN2 74 M AML/MDS Normal Refractory to chemotherapy CD34+CD38− predominant
UPN3 43 F AML/MDS 7q− Evolved from MDS CD34+CD38− predominant
UPN4 77 F AML/MPD-PV t(2;6),del(3), −4 De novo CD34+CD38− predominant
UPN5 42 M AML-FLT3ITD Normal Relapse CD34+CD38+ predominant
UPN6 23 M AML/MDS Complex Relapse CD34+CD38+ predominant
UPN7 39 M M5 7q- Refractory to chemotherapy CD34+CD38+ predominant
UPN8 57 M AML/MDS 7q- De novo CD34+CD38+ predominant
Abbreviations: AML, acute myeloid leukemia; LSC, leukemic stem cell; MDS, myelodysplastic syndrome; MPD, myeloproliferative disease;
PV, polycythemia vera.
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compartment.
Leukemic phenotype and cell cycle analysis
The phenotype of cultured cells was analyzed weekly using
fluorescently-conjugated monoclonal antibodies against
CD38-FITC (clone IM0775U), CD34-PECy7 (clone 8G12),
CD11b-APCCy7 (clone ICRF44), CD123-PECy5 (clone 9F5),
and CD45-V500 (clone HI30), in addition to the lineage
panel (CD2, CD3, CD14, CD19—Pacific Blue). Cells were
also stained with Annexin V-APC (BD Biosciences, San Jose,
CA) and PI and the proportion of viable, non-apoptotic cells
was evaluated in Annexin V negative and PI negative
populations. Admixed CD45 negative MSCs were easily
distinguished from the CD45 positive leukemic cells.
Stained cells were acquired on a FACS Canto II (BD
Biosciences). For cell cycle analysis, at least 1 million
viable cells were first stained with CD34-PECy7, CD45-APC
(BD Biosciences) for 15 min at room temperature. After
washing, the cells were incubated at 37 °C, 5% CO2 for
45 min in 2 μM Hoechst 33342 solution (Molecular Probes,
Eugene, OR). Pyronin Y 1 μg/ml (Polysciences, Inc. War-
rington, PA) was added and incubation continued for
another 45 min at 37 °C, 5% CO2. After washing, PI was
added to the cells before acquiring on an LSRII (BD,
Franklin Lakes, NJ). All flow cytometry data were analyzed
using FlowJo software (Tree Star Inc., Ashland, OR). The
fraction of cells in the G0, G1, S-G2-M phases of the cell
cycle was determined by gating on cell populations defined
by their DNA and RNA contents.
Transplantation of leukemic cells into immune
deficient mice
Non-obese diabetic/severe combined immunodeficiency
IL-2Rγnull (NSG) mice were purchased from Jackson
Laboratories (Bar Harbor, ME) and maintained under
specific pathogen-free conditions. 6–8 week old mice (2–
5 mice/group) were sublethally irradiated (300 cGy) 18–
24 h before transplantation. For limiting dilution analysis,
specific CD34+ cell doses of primary leukemic samples
ranging from 5 × 103 to 5 × 105 were injected into at least
5 NSG mice per dose. To evaluate the engraftment capacity
of MSC co-cultured cells, CD45+ leukemic cells were sorted4–6 weeks after co-culture, and injected into irradiated
mice through tail-vein injection. Equivalent numbers of
CD34+ leukemic cells freshly sorted from primary leukemic
samples were used as controls. At week 8 after transplan-
tation, mice were sacrificed and BM cells were harvested
from both femurs and tibias. Cells were stained with
human-CD45-PE, CD34-PECy7, CD38-FITC, CD123-PECy5,
CD90-APC, CD45RA- and human leukemia engraftment was
defined as a threshold of 0.1% human CD45+CD34+ cells in
total viable BM cells. The animal experiments were
approved by the Animal Care and Use Committee of the
National Institutes of Health.
Cytogenetic analysis and spectral karyotyping (SKY)
Samples from the original uncultured Lin−CD34+ sorted
leukemic blasts, as well as from Lin−CD45+ leukemic blasts
sorted 4–6 weeks after MSC co-culture or 2 months after
NSG transplantation were used for metaphase preparations.
After mitotic arrest with colcemid (0.015 lg/ml, 2–4 h)
(GIBCO, Gaithersburg, MD) and hypotonic treatment
(0.075 mol/l KCl, 20 min, 37 °C), the cells were fixed with
methanol–acetic acid (3:1) (Schrock et al., 1996). Spectral
karyotyping (Applied Spectral Imaging INC, Carlsbad, CA)
and DAPI banding techniques were performed to identify
structural and numerical chromosome aberrations and clonal
evolution during culture. Clones were defined and karyo-
types were designated according to the ISCN (2009) (Shaffer
et al., 2009).
Chemosensitivity assay to cytarabine
Lin−CD34+ leukemic blasts were first labeled with CFSE
(Vybrant® CFDA SE Cell Tracer Kit, Life Technologies, NY)
according to the manufacturer's instructions. CFSE-labeled
CD34+ blasts (2 × 104 cells) were co-cultured with or
without an equal number of irradiated MSCs (2 × 104
cells) in 96 well flat bottom plates. Serial dilutions of
cytarabine (Bedford Laboratories, OH) from 10 μM to
0.5 μM were added to each well, and the cells were
incubated at 37 °C, 5% CO2 for 48 h. Leukemic blasts were
then harvested from each well and the percentage of
Annexin V- and PI-negative viable cells was determined in
CFSE-labeled cells using FACS Fortessa. Relative viability
was calculated using the formula: % relative viability =
98 S. Ito et al.100 − (a / b × 100) where a is the percentage of viable
cells with or without MSCs in different doses of cytarabine
and b is the percentage viable cells co-culture with MSCs in
the absence of cytarabine.
Statistical analysis
Data were analyzed with Prism Version 5.04 (GraphPad
Software, Inc. La Jolla, CA). Results were considered
statistically significant if a p value was found to be less
than 0.05 based on one-way ANOVA analysis and paired
t-test. The frequency of LSCs was calculated using L-Calc
software (StemSoft Software Inc., Vancouver, CA).
Results
Primary leukemic cell surface phenotypes
are heterogeneous
We characterized surface markers of eight AML blasts on
the basis of CD34 and CD38 expression within the lineage
(CD2/CD3/CD14/CD19) negative population. Primary leu-
kemic samples were phenotypically heterogeneous as
previously reported (Eppert et al., 2011; Sarry et al.,
2011). Based on the proportions of cells co-staining for
CD34 and CD38, we classified leukemic samples as CD34+
CD38− predominant leukemias (n = 4) and CD34+CD38+
predominant leukemias (n = 4) (Supplementary Fig. 1).
The latter group included both CMP- and GMP-like leuke-
mias (Supplementary Fig. 2).
Co-culture with MSCs maintains viable leukemic
blasts in vitro
Sorted CD34+ blasts from primary leukemias were cultured
in different conditions as follows: 1) co-culture with MSCs; 2)
co-culture with MSCs in a cytokine cocktail consisting of
Flt3L, SCF, and IL-3; 3) culture in a cytokine cocktail alone;
or 4) culture in human cell culture medium only (medium
alone). All leukemic blasts retained significantly higher
viable absolute counts after at least 4 weeks when
co-cultured with MSCs (38 ± 17 × 103 cells: p = 0.01),
MSCs + cytokines (193 ± 108 × 103 cells: p = 0.04), or cyto-
kines (163 ± 83 × 103 cells: p = 0.01) compared to medium
alone (5 ± 3 × 103 cells) except one outlier sample (UPN1)
which maintained viable cells even in medium alone
(Supplementary Fig. 3). MSCs maintained all CD34+ CD38−
predominant leukemic cells viable for up to 6 weeks (Figs.
1A and C). In contrast, CD34+ CD38+ predominant leukemic
samples remained viable for only 4 weeks when co-cultured
with cytokines with or without MSCs (Fig. 1B).
Co-culture with MSCs maintains the surface
phenotype of the primary leukemias in vitro
We evaluated the cell surface phenotype of cultured
leukemic cells weekly in each culture condition. CD34+
CD38− predominant leukemic samples (n = 4) maintained
the original CD34+CD38− phenotype when co-cultured with
MSCs at 6 weeks, in contrast to cultures with MSCs + cytokines(p = 0.03), cytokines (p = 0.03), or medium alone (p = 0.03)
which showed rapid decline of the CD34+ CD38− phenotype
within two weeks (Fig. 2A). CD34+ CD38+ predominant
leukemias (n = 4) also maintained their CD34+CD38+ pheno-
type when co-cultured with MSCs at 2 weeks compared with
MSCs + cytokines (p = 0.05), cytokines (p = 0.03), or medi-
um alone (p = 0.03) (Fig. 2B). Absolute numbers of
CD34+CD38− cells were highest in MSCs or MSCs + cytokines
conditions in all CD34+ CD38− predominant leukemias
(Fig. 2C). Similarly, absolute numbers of CD34+CD38+ cells
were highest in MSCs or MSCs + cytokines conditions in all
CD34+ CD38+ predominant leukemias (Fig. 2D). Cells
cultured in a cytokine cocktail lost CD34 expression rapidly,
suggesting differentiation of the leukemic blasts, while
cells co-cultured with MSCs remained undifferentiated as
shown in Fig. 2E. The total number of viable leukemic cells
and the persistence of the original leukemic phenotype
were significantly diminished when leukemic cells were
separated from MSCs in a transwell culture system as
compared to co-culture conditions allowing direct
cell-to-cell contact between MSCs and leukemic blasts
(Supplementary Fig. 4).Leukemic blasts remained quiescent when
co-cultured with MSCs
Cell cycle analysis was performed 1 and 2 weeks after
initiation of in vitro culture. A higher proportion of
CD45+CD34+ leukemic blasts remained in G0 when
co-cultured with MSCs (average 51.1 ± 5.1% for all 8
leukemias) compared to cultures in either MSCs + cytokines
(34.8 ± 5.1%; p = 0.01) or cytokines (34.2 ± 4.3%; p = 0.05,
Figs. 3A and B). The G0/G1 ratio was also higher when
leukemic cells were co-cultured with MSCs (2.0 ± 0.36)
compared to cultures in either MSCs + cytokines (0.99 ±
0.25; p = 0.01) or cytokines (0.99 ± 0.28; p = 0.05). Abso-
lute numbers of G0 cells were not significantly different with
or without MSCs (Figs. 3C and D). These findings indicate
that co-culture with MSCs favored quiescence in leukemic
blasts and minimized cell cycling compared to culture
conditions utilizing cytokines.CD34+ CD38− predominant leukemic blasts contain
higher frequencies of leukemia initiating cells
engrafting in NSG mice
The frequency of leukemia initiating cells in the primary
leukemias was evaluated by limiting dilution analysis using
two representative samples, UPN1 (CD34+ CD38− predomi-
nant leukemia) and UPN6 (CD34+ CD38+ predominant
leukemia). Eight weeks after injecting a specific dose of
sorted leukemic blasts (5 × 103 to 5 × 105), both leukemias
successfully engrafted as defined by more than 0.1% CD45+
CD34+ cells in the bone marrow. The calculated frequency of
leukemia initiating cells (LIC) was superior in the CD34+
CD38− predominant leukemic sample tested (1 LIC per
2.7 × 103, 95% CI: 1.6–4.6 × 103) compared to the CD34+
CD38+ predominant leukemic sample studied (1 LIC per
3.8 × 105, 95% CI: 2.3–6.4 × 105) (p = 0.0003).
Figure 1 Numbers of viable AML blasts generated during culture. (A) Trend of absolute numbers of viable LSC-like leukemic blasts
excluding UPN1 (separately shown in Supplementary Fig. 2). Better viability of leukemic blasts was observed when co-cultured with
MSCs, MSCs supplemented with cytokines (MSCs + Cyto) (IL-3, Flt3-ligand, and SCF), cytokines alone (Cyto) in contrast to medium only
(Medium). (B) Trend of absolute numbers of viable non-LSC-like leukemic blasts. (C) Microscopic appearance of leukemic blasts
co-cultured with MSCs. Representative images for UPN3 (CD34+ CD38− predominant leukemia) indicating preserved morphology of
leukemic blasts cultured for 2 weeks in the presence (middle panel) or absence (right panel) of MSCs.
99Long term maintenance of AML stem cells with MSCsLeukemic blasts in long-term MSC co-culture
systems successfully engraft in NSG mice
We repeated xenotransplantation experiments to confirm
the persistence of leukemia initiating cells after MSC
co-culture. We cultured UPN1 and UPN6 on MSCs for
6 weeks and 4 weeks respectively, and then injected
equivalent numbers of sorted CD45+ leukemic blasts from
MSC co-cultures and non-cultured CD34+ leukemic blasts.
Both leukemias successfully engrafted in NSG mice in
8 weeks achieving equivalent proportions of CD45+ cell
engraftment compared to freshly sorted leukemic cells
(UPN1: p = 0.54 and UPN6: p = 0.99 respectively: Fig. 4A).
Engrafted cells retained the original phenotypes in both
CD34+ CD38− predominant and CD34+ CD38+ predominantsamples (Fig. 4B). These results confirmed the maintenance
of leukemia initiating cells after long-term in vitro
co-culture with MSCs.Maintenance of the leukemic clones after co-culture
with MSCs
The original chromosomal aberrations found in UPN1 and
UPN6 were monitored at different time points: 1) in fresh
CD34+ sorted blasts prior to MSC co-culture; 2) in CD45+
sorted blasts 6 weeks after MSC co-culture; and 3) in CD45+
blasts sorted from the bone marrow of NSG mice 8 weeks
after transplantation. The chromosomal abnormalities in
the original samples persisted after MSC co-culture and
Figure 2 Phenotype of AML blasts during culture. (A) Percentage of CD34+CD38− cells in CD34+ CD38− predominant leukemic
samples during culture with MSCs, MSCs with cytokines (MSCs + Cyto), cytokines alone (Cyto), or medium alone (Medium). CD34+
CD38− predominant leukemias (average %CD34+CD38− 72.5%; range 55.6–90.0% at day 0)maintained a higher proportion of CD34+CD38− cells
when co-cultured with MSCs compared to other culture conditions. (B) Percentage of CD34+CD38+ cells in CD34+ CD38+ predominant (average
%CD34+CD38+ 55.6%; range 30.3–89.9% at day 0) leukemic samples during culture. CD34+ CD38+ predominant leukemias maintained a higher
proportion of CD34+CD38+ cells when co-cultured with MSCs. (C) Trend of absolute numbers of viable CD34+CD38− cells in CD34+ CD38−
predominant leukemic blasts excluding UPN1 (separately shown in Supplementary Fig. 2). (D) Trend of absolute numbers of viable
CD34+CD38+ cells in CD34+ CD38+ predominant leukemic blasts. (E) Representative immunophenotype data of CD45+ leukemic blasts from
patient UPN4 (CD34+ CD38− predominant leukemia) and UPN6 (CD34+ CD38+ predominant leukemia) during culture. Co-culture with MSCs
favored persistence of the original phenotype compared to other culture conditions.
100 S. Ito et al.engraftment of MSC co-cultured cells in NSG mice; however
other chromosomal aberrations were found (Fig. 5A and B).MSCs promote chemotherapy resistance in
leukemic blasts
To evaluate the impact of MSCs on the function of leukemic
blasts, we performed a chemosensitivity assay to cytara-
bine. Six primary leukemic blast samples (Lin−CD34+ cells
from CD34+ CD38− predominant (n = 3) and CD34+ CD38+
predominant leukemias (n = 3)) were incubated for 48 h
with serial dilutions of cytarabine with or without MSCs.
The viability of leukemic blasts was significantly higher
with less apoptotic cells when co-cultured with MSCs (p =
0.0009: Fig. 6). This finding indicates that MSCs providepro-survival benefit, protecting primary leukemic cells
from chemotherapy.Discussion
BM-derived MSCs represent part of the multicellular stromal
support that creates a milieu to maintain HSC function and
allow growth and differentiation of hematopoietic progen-
itors. The ease with which MSCs can be expanded in vitro
facilitates the study of the interaction of MSCs with
hematopoietic progenitors. MSCs have been successfully
employed to increase the hematopoietic stem and progen-
itor cell numbers in cord blood for transplantation (de Lima
et al., 2012). A current interest is whether the marrow
milieu is also supportive to AML stem cells and represents a
Figure 3 Cell cycle analysis of AML blasts during culture. (A) Representative cell cycle analysis of UPN2 (CD34+ CD38– predominant
leukemia) 1 week after culture with MSCs, MSCs with cytokines (MSCs + Cyto), or cytokines alone (Cyto). (B) Summary of cell cycle
analysis before co-culture and 1 week after co-culture (n = 8). A higher proportion of cells remained in G0 when co-cultured with
MSCs compared to other culture conditions using cytokines. (C) Trend of absolute numbers of CD34+ CD38− predominant leukemic
cells in the G0 phase of the cell cycle. (D) Trend of absolute numbers of CD34+ CD38+ predominant leukemic cells in the G0 phase of
the cell cycle.
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standing the nature of the stroma-LSC interactions would
inform more effective therapy to eliminate residual leuke-
mia persisting after induction chemotherapy. Furthermore
an in vitro stromal/LSC co-culture system that replicates
favorable conditions for LSC persistence would serve as a
more relevant model for testing agents active against LSCs.
In this study, we demonstrated that unrelated allogeneic
human MSCs supported a LSC phenotype in a largely
quiescent state in a long-term vitro culture system. We
then confirmed the persistence of LIC after 6 weeks
co-culture with MSCs using the NSG mouse xenotransplant
model. Our results also revealed that MSCs, in contrast tococktails of stem cell growth factors or medium alone,
support survival of quiescent LSCs with minimal outgrowth of
more differentiated leukemic populations. Of interest, for
one of 8 leukemic samples studied, LSCs were maintained in
culture for up to 6 weeks even without MSC support.
Variability between leukemic samples has been described
before (Klco et al., 2013). While the mechanisms underlying
the atypical in vitro growth pattern of leukemic blasts in this
patient remain unclear, we have observed increased
telomere length in this sample compared to leukemic cells
derived from age-matched patients (unpublished data). The
maintenance of viable leukemic blasts in a stromal
co-culture system is consistent with the previous findings
Figure 4 Transplantation of AML blasts in NSG mice. (A) Summary (post MSCs, n = 5 mice; uncultured, n = 2 mice) and (B)
representative experiment of human cell engraftment in the bone marrow of NSG mice 8 weeks after transplantation. Both leukemic
blasts harvested 4 and 6 weeks after MSC co-culture, respectively, maintained their ability to engraft compared to uncultured blasts
derived from the original leukemic samples. The engrafted cells retained the original phenotypes regarding to CD34 and CD38
expression.
102 S. Ito et al.observed by van Gosliga et al (van Gosliga et al., 2007) using
murine MS5 stromal cell lines and by Klco et al (Klco et al.,
2013) using human HS27 stromal cell lines to expand primary
AML blasts. However, both groups combined MSCs with
growth factors (SCF, IL-3, Flt-3 ligand +/− TPO), and one
study demonstrated loss of the CD34+ cell population after
long-term co-culture (van Gosliga et al., 2007). While the
distinct stromal cells utilized in each study may account for
the differences observed, our data suggest that addition of
growth factors during co-culture results in depletion of LSCs
by promoting their differentiation in vitro.
We also demonstrated that the protective effect on
LSCs requires direct cell-to-cell contact since a transwell
culture system failed to replicate the findings in vitro. The
nature of the interactions between MSCs and leukemic
blasts that favor survival, quiescence and maintenance
of the original phenotype remains to be elucidated.
Despite the prolonged culture (and in keeping with thepreservation of quiescence) we found that the clonality of
the original leukemic population was largely preserved by
MSCs. This ability of MSCs to preserve the original leukemic
phenotype was observed more significantly in CD34+ CD38−
predominant leukemias than CD34+ CD38+ predominant
leukemias. The non-LSC-like leukemias had two logs fewer
leukemia initiating cells than the LSC samples, thus the
preferential pro-survival effects of MSCs in vitro may be
largely restricted to preserving leukemic stem cells.
Further studies to identify the mechanisms of LSC support
by MSCs should shed light on the role of MSCs in the marrow
milieu.
While remission induction has continued to improve in
patients with AML, disease relapse remains a major
limitation for cure. We showed that leukemic blasts
maintained on MSCs were more resistant to cytotoxicity
from cytarabine, a widely used nucleoside analogue to
induce remission in AML. Currently allogeneic stem cell
Figure 5 Cytogenetic analysis of leukemic blasts. (A) Representative images of spectral karyotype analysis (SKY) and (B)
cytogenetic abnormalities from clones found in leukemic blasts. For both UPN1 blasts (CD34+ CD38– predominant leukemia) and UPN6
blasts (CD34+ CD38+ predominant leukemia), the original chromosomal abnormalities (upper panels) persisted in CD45+ blasts sorted
6 weeks after MSC co-culture (middle panels) as well as in CD45+ blasts sorted from the bone marrow of NSG mice 8 weeks after
transplantation (lower panels). Additional chromosomal aberrations were also detected.
Figure 6 Chemosensitivity of leukemic blasts to cytarabine.
Cells from six primary leukemic samples were cultured for 48 h
with or without MSCs in the presence of different doses of
cytarabine. Data are represented as a relative percentage of
viability compared MSC co-cultured blasts. The viability of
leukemic blasts was significantly higher when co-cultured with
MSCs.
103Long term maintenance of AML stem cells with MSCstransplantation represents one of the most reliable strategies
for eliminating residual disease through a graft-versus-leukemia
(GVL) effect. Leukemic cells capable of initiating leukemia in a
xenograft model are currently the best descriptor of the cell
type responsible for leukemic relapse after chemotherapy. Our
in vitromodel could be used to study interactions of alloreactive
lymphocytes with GVL-like effects on LSCs as well as to explore
new agents with specificity for quiescent LSCs. While we show
differences in the supportive capacity of MSCs for CD34+ CD38−
predominant and CD34+ CD38+ predominant leukemias, addi-
tional studies will be needed to clarify the nature of MSC
interactions with specific AML subtypes, and to correlate LSC
maintenance in vitro with relapse probability in vivo.Conclusion
Co-culture of leukemic blasts with MSCs represents a
simple approach to maintain leukemia initiating cells in
104 S. Ito et al.vitro. This culture system will permit exploration of the
protective effects of the marrow microenvironment on
leukemic stem cells and serve as an improved method to
explore therapeutic approaches targeting the leukemic
stem cell.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.scr.2014.11.007.
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